These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20684144)

  • 1. Treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with psoriasis.
    DiBonaventura Md; Wagner S; Waters H; Carter C
    J Drugs Dermatol; 2010 Aug; 9(8):938-44. PubMed ID: 20684144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
    Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 15% azelaic acid in psoriasis vulgaris: a randomized, controlled clinical trial.
    Iraji F; Faghihi G; Siadat AH; Enshaieh S; Shahmoradi Z; Joia A; Soleimani F
    J Drugs Dermatol; 2010 Aug; 9(8):964-8. PubMed ID: 20684146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DESIRE study--psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice.
    Claréus BW; Houwing R; Sindrup JH; Wigchert S
    Eur J Dermatol; 2009; 19(6):581-5. PubMed ID: 19726275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction with treatment among patients with psoriasis: a web-based survey study.
    van Cranenburgh OD; de Korte J; Sprangers MA; de Rie MA; Smets EM
    Br J Dermatol; 2013 Aug; 169(2):398-405. PubMed ID: 23565643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity.
    Vaidya TS; Anderson KL; Feldman SR
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment goals in psoriasis.
    Reich K; Mrowietz U
    J Dtsch Dermatol Ges; 2007 Jul; 5(7):566-74. PubMed ID: 17610606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW; Robertson AD; Wu J; Schupp C; Lebwohl MG
    JAMA Dermatol; 2013 Oct; 149(10):1180-5. PubMed ID: 23945732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
    van de Kerkhof PC; van der Valk PG; Swinkels OQ; Kucharekova M; de Rie MA; de Vries HJ; Damstra R; Oranje AP; de Waard-van der Spek FB; van Neer P; Lijnen RL; Kunkeler AC; van Hees C; Haertlein NG; Hol CW
    Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience.
    Gokdemir G; Ari S; Köşlü A
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):330-5. PubMed ID: 18269601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.
    Dubertret L; Mrowietz U; Ranki A; van de Kerkhof PC; Chimenti S; Lotti T; Schäfer G;
    Br J Dermatol; 2006 Oct; 155(4):729-36. PubMed ID: 16965422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme.
    de Korte J; Van Onselen J; Kownacki S; Sprangers MA; Bos JD
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):35-41. PubMed ID: 15649189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis.
    Mraz S; Leonardi C; Colón LE; Johnson LA
    J Dermatolog Treat; 2008; 19(6):354-9. PubMed ID: 18923991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years.
    Zampetti A; Barone A; Antuzzi D; Amerio P; Tulli A; Feliciani C; Amerio P
    J Dermatolog Treat; 2008; 19(3):134-40. PubMed ID: 18569269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing use of more potent treatments for psoriasis.
    Strowd LC; Yentzer BA; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2009 Mar; 60(3):478-81. PubMed ID: 19058875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What are the objectives of moderate to severe psoriasis treatment?].
    Ortonne JP
    Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.